In this study, we developed a hepatocellular carcinoma (HCC)-specific gene therapy system by expressing a dominant negative mutant form of the PP2A catalytic subunit under direct transcriptional control of the AFP enhancer/pgk promoter, and investigated the therapeutic effects of this system in HCC in vitro and in vivo. The gene discussed is PRKG1; the disease is hepatocellular carcinoma.